Literature DB >> 27698099

BCL2 Inhibition by Venetoclax: Targeting the Achilles' Heel of the Acute Myeloid Leukemia Stem Cell?

Vinod A Pullarkat1, Edward M Newman2.   

Abstract

Venetoclax is an oral drug with an excellent side-effect profile that has the potential to revolutionize acute myeloid leukemia (AML) therapy in two areas. Venetoclax-based combination therapies could be a bridge to hematopoietic cell transplant with curative intent for patients with refractory/relapsed AML, and venetoclax-based therapy could provide meaningful survival prolongation for older patients with AML who are not candidates for more aggressive therapies. Cancer Discov; 6(10); 1082-3. ©2016 AACR.See related article by Konopleva and colleagues, p. 1106. ©2016 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27698099     DOI： 10.1158/2159-8290.CD-16-0921

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  8 in total

Review 1.  Reporters of Cancer Stem Cells as a Tool for Drug Discovery.

Authors:  Amrutha Mohan; Reshma Raj R; Gayathri Mohan; Padmaja K P; Tessy Thomas Maliekal
Journal:  Front Oncol       Date:  2021-04-22       Impact factor: 6.244

2.  FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation.

Authors:  Ruiqi Zhu; Li Li; Bao Nguyen; Jaesung Seo; Min Wu; Tessa Seale; Mark Levis; Amy Duffield; Yu Hu; Donald Small
Journal:  Signal Transduct Target Ther       Date:  2021-05-24

Review 3.  Targeting Mitochondrial Bioenergetics as a Therapeutic Strategy for Chronic Lymphocytic Leukemia.

Authors:  Subir Roy Chowdhury; Versha Banerji
Journal:  Oxid Med Cell Longev       Date:  2018-02-28       Impact factor: 6.543

4.  Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells.

Authors:  Daniel A Luedtke; Xiaojia Niu; Yihang Pan; Jianyun Zhao; Shuang Liu; Holly Edwards; Kang Chen; Hai Lin; Jeffrey W Taub; Yubin Ge
Journal:  Signal Transduct Target Ther       Date:  2017-04-07

Review 5.  Epigenetic therapy combinations in acute myeloid leukemia: what are the options?

Authors:  Jan Philipp Bewersdorf; Rory Shallis; Maximilian Stahl; Amer M Zeidan
Journal:  Ther Adv Hematol       Date:  2019-01-11

Review 6.  Targeting BCL-2 in Cancer: Advances, Challenges, and Perspectives.

Authors:  Shirin Hafezi; Mohamed Rahmani
Journal:  Cancers (Basel)       Date:  2021-03-14       Impact factor: 6.639

7.  An integrative systems biology approach to overcome venetoclax resistance in acute myeloid leukemia.

Authors:  Michelle Przedborski; David Sharon; Severine Cathelin; Steven Chan; Mohammad Kohandel
Journal:  PLoS Comput Biol       Date:  2022-09-13       Impact factor: 4.779

8.  Inhibition of XPO1 enhances cell death induced by ABT-199 in acute myeloid leukaemia via Mcl-1.

Authors:  Daniel A Luedtke; Yongwei Su; Shuang Liu; Holly Edwards; Yue Wang; Hai Lin; Jeffrey W Taub; Yubin Ge
Journal:  J Cell Mol Med       Date:  2018-09-14       Impact factor: 5.310
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.